Pharmacophore an International Research Journal
Cardiovascular disease (CVD) and its complications are the most common causes of mortality and morbidity worldwide. It is shown that patients with myocardial infarctions (MIs) have high platelets activation and aggregation rates which lead to atherothrombosis after the rupture of an unstable atherosclerotic plaque. Therefore, antiplatelet therapy has become an important part of the secondary prevention of cardiovascular disease. To provide a review about the role of antiplatelet medications in preventing cardiovascular disease and its complications. The articles were selected in regards to the inclusion criteria, based on the incorporation of one of the following topics: antiplatelet action in cardiovascular disease. Exclusion principles were all other articles, which did not have one of these topics as their essential endpoint. PubMed database was utilized for articles selection, and the following keys were used in the mesh ((“antiplatelet"[Mesh]) AND (“cardiovascular disease” [Mesh]) OR (“DAPT"[Mesh])).
Aspirin was the first antiplatelet medicine identified, and it is still recommended as the first line of defense in the secondary prevention of cardiovascular disease. For many years, clopidogrel has been the predominant P2Y12 inhibitor in the acute context. peripheral angioplasty with stenting or Following elective percutaneous coronary intercession (PCI), the state-of-the-art dual antiplatelet treatment (DAPT) regimen includes clopidogrel plus aspirin. The appropriate DAPT length following stent implantation has been a topic of extreme controversy and considerable scientific interest. More research is necessary to determine the optimal duration that is safe and effective for post-PCI patients
